Clinical trials: Metastatic Colorectal Carcinoma
Lung Metastasis, Colorectal Cancer
Radiofrequency Ablation in Resectable Colorectal Lung Metastasis
Lung metastasectomy is the only therapeutic option to provide a long-survival in patients with colorectal lung metastases. Recent studies have shown that radiofrequency (RF) ablation is a safe and useful therapeutic option for…
- Trial name
- NCT00776399
- Testing
- Lung radiofrequency ablation
- Where
- 16 sites in Japan
- Volunteers
- 70 people
- Sponsor
- Mie University
Metastatic Colorectal Cancer
AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients
The aim of this study is to evaluate the efficacy of mFOLFOXIRI plus cetuximab and avelumab as first line treatment of patients with initially unresectable and previously untreated RAS wild-type metastatic colorectal cancer…
- Trial name
- AVETRIC (NCT04513951)
- Testing
- 5Fluorouracil, L-leucovorin, Irinotecan
- Where
- Italy
- Volunteers
- 62 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Cancer
Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen
RATIONALE: Antiemetic drugs may help to reduce or prevent vomiting in patients treated with radiation therapy. It is not yet known if ondansetron is more effective with or without dexamethasone in preventing vomiting caused by…
- Trial name
- NCT00016380
- Testing
- dexamethasone, ondansetron, quality-of-life assessment
- Where
- 14 sites in Canada
- Volunteers
- 211 people
- Sponsor
- NCIC Clinical Trials Group
Colorectal Cancer
A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer
This study will evaluate the efficacy, safety, and pharmacoeconomics of oral capecitabine in patients with metastatic colorectal cancer.
- Trial name
- NCT02567331
- Testing
- Capecitabine
- Where
- 5 sites in Bulgaria
- Volunteers
- 28 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumor, Metastatic Solid Tumor
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT05824975
- Testing
- GI-102 subcutaneous (SC), GI-102, doxorubicin
- Where
- 11 sites in United States, South Korea
- Volunteers
- 358 people
- Sponsor
- GI Innovation, Inc.
Colo-rectal Cancer
The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts
This is an open label, multicenter, randomized study in Chinese patients with RAS and BRAF wild-type mCRC. Participants were randomly assigned to cetuximab + FOLFOX (group A) and cetuximab + modified XELOX[mXELOX] (group B).
- Trial name
- NCT05074966
- Testing
- Experimental: mXELOX plus cetuximab, Active Comparator: FOLFOX plus cetuximab
- Where
- China
- Volunteers
- 314 people
- Sponsor
- Chinese Academy of Medical Sciences
Solid Cancer
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
The purpose of this study is to enable participants, currently receiving regorafenib in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed.
- Trial name
- NCT03890731
- Testing
- BAY73-4506 (Regorafenib, Stivarga)
- Where
- 6 sites in United States, Germany and 3 more
- Volunteers
- 6 people
- Sponsor
- Bayer
Colorectal Cancer
Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003001
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Stony Brook University
Colorectal Cancer
Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer
The survival of the refractory CRC is dismal and therapy options are limited ，the researchers aim to investigate the efficacy, safety, and predictors of fruquintinib plus PD-1 in refractory MSS metastatic colorectal cancer in a…
- Trial name
- NCT06011330
- Testing
- Fruquintinib combined with anti-PD-1 antibodies
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Hunan Cancer Hospital
Metastatic Colorectal Cancer
Recombinant Anti-tumor and Anti-virus Protein for Injection Plus Xeloda in Treatment of Metastatic Colorectal Cancer
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-tumor and anti-virus protein for injection plus capecitabine in treating patients with metastatic colorectal cancer who have progressed after…
- Trial name
- NCT02068131
- Testing
- Novaferon, Capecitabine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Colorectal Cancer, Breast Cancer
Impact of Aerobic Exercise on the Anticancer Immune Response in Patients Receiving Cancer Treatment
The goal of this clinical trial is to determine to what extent anticancer immune cells mobilized by aerobic exercise exhibit migratory and functional capacity towards cancer cells in patients undergoing treatment for breast or…
- Conditions
- Colorectal Cancer, Breast Cancer, Non Metastatic Cancer
- Trial name
- Immuno-Ex (NCT06911970)
- Testing
- Exercise
- Where
- 2 sites in Canada
- Volunteers
- 44 people
- Sponsor
- Université de Sherbrooke
Cancer
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00096083
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Delcath Systems Inc.
Colorectal Cancer
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer
- Trial name
- TARGET-D 203 (NCT07659795)
- Testing
- VS-7375, cetuximab, panitumumab
- Where
- 30 sites in United States, Australia
- Volunteers
- 150 people
- Sponsor
- Verastem, Inc.
Metastatic Colorectal Cancer
Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer
A prospective, multicenter, randomized in a 2:1 ratio, controlled, clinical trial with two parallel arms will be conducted to compare irinotecan dose escalated FOLFIRI according to UGT1A1 genotyping plus 120 mg regorafenib with…
- Trial name
- NCT03880877
- Testing
- Regorafenib, UGT1A1 genotyping (TA6/TA6), UGT1A1 genotyping (TA6/TA7)
- Where
- Taiwan
- Volunteers
- 153 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
RAS Mutation, Metastatic Colorectal Cancer
ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
This is a non-profit phase II, open, clinical study of the combination of irinotecan plus cetuximab and envafolimab as a rechallenge regimen, in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients (according to…
- Conditions
- RAS Mutation, Metastatic Colorectal Cancer, MSS
- Trial name
- NCT06321081
- Testing
- irinotecan, cetuximab, envafolimab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Hospital
Metastatic Colorectal Cancer
Xeloda Maintenance Versus BSC in Metastatic Colorectal Cancer
Colorectal cancer (CRC) accounts for 10% to 15% of all cancers and is the second leading cause of cancer deaths in Western countries.
- Trial name
- NCT02060669
- Testing
- Xeloda
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Samsung Medical Center
Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Microsatellite Stable Colorectal Carcinoma
Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
This phase I trial tests the safety, side effects, and best dose of abemaciclib in combination with 5-fluorouracil and how well it works in treating patients with colorectal cancer that has spread from where it first started…
- Conditions
- Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Microsatellite Stable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
- Trial name
- NCT06654037
- Testing
- Abemaciclib, Biopsy Procedure, Biospecimen Collection
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
This is a phase 1/1b open label, multicenter dose escalation and dose expansion study to investigate the safety, tolerability and anti-tumor activity of TPST-1120, a small molecule selective antagonist of PPARα (peroxisome…
- Conditions
- Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT03829436
- Testing
- Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- Tempest Therapeutics
Metastatic Colorectal Cancer
Pattern of Cell Death Following Neoadjuvant Therapy for Metastatic Colon Cancer
Systemic chemotherapy for metastatic colon cancer is often used in the neoadjuvant setting for patients undergoing liver resection.
- Trial name
- NCT00414492
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colon Cancer
Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer
This trial will evaluate the combination of modified infusional 5-fluorouracil/ leucovorin, oxaliplatin (FOLFOX6), bevacizumab, and cetuximab in patients with metastatic colorectal cancer.
- Trial name
- NCT00193219
- Testing
- Bevacizumab, Cetuximab, 5-fluorouracil
- Where
- 10 sites in United States
- Volunteers
- 36 people
- Sponsor
- SCRI Development Innovations, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.